189 related articles for article (PubMed ID: 34443317)
1. Iloprost Attenuates Oxidative Stress-Dependent Activation of Collagen Synthesis Induced by Sera from Scleroderma Patients in Human Pulmonary Microvascular Endothelial Cells.
Giordo R; Thuan DTB; Posadino AM; Cossu A; Zinellu A; Erre GL; Pintus G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443317
[TBL] [Abstract][Full Text] [Related]
2. The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.
Colasanti T; Stefanantoni K; Fantini C; Corinaldesi C; Vasile M; Marampon F; Di Luigi L; Antinozzi C; Sgrò P; Lenzi A; Riccieri V; Crescioli C
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077548
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.
Balbir-Gurman A; Braun-Moscovici Y; Livshitz V; Schapira D; Markovits D; Rozin A; Boikaner T; Nahir AM
Clin Rheumatol; 2007 Sep; 26(9):1517-21. PubMed ID: 17401513
[TBL] [Abstract][Full Text] [Related]
4. NADPH-derived ROS generation drives fibrosis and endothelial-to-mesenchymal transition in systemic sclerosis: Potential cross talk with circulating miRNAs.
Posadino AM; Erre GL; Cossu A; Emanueli C; Eid AH; Zinellu A; Pintus G; Giordo R
Biomol Concepts; 2022 Feb; 13(1):11-24. PubMed ID: 35189048
[TBL] [Abstract][Full Text] [Related]
5. Iloprost therapy acutely decreases oxidative stress in patients affected by systemic sclerosis.
Erre GL; De Muro P; Dellacà P; Fenu P; Cherchi GM; Faedda R; Passiu G
Clin Exp Rheumatol; 2008; 26(6):1095-8. PubMed ID: 19210877
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis.
Chora I; Romano E; Manetti M; Mazzotta C; Costa R; Machado V; Cortez A; Bruni C; Lepri G; Guiducci S; De Paulis A; Soares R; Matucci-Cerinic M
J Rheumatol; 2017 Aug; 44(8):1190-1197. PubMed ID: 28507177
[TBL] [Abstract][Full Text] [Related]
7. The
Kavian N; Mehlal S; Jeljeli M; Saidu NEB; Nicco C; Cerles O; Chouzenoux S; Cauvet A; Camus C; Ait-Djoudi M; Chéreau C; Kerdine-Römer S; Allanore Y; Batteux F
Front Immunol; 2018; 9():1896. PubMed ID: 30177933
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies.
Ahmed SS; Tan FK; Arnett FC; Jin L; Geng YJ
Arthritis Rheum; 2006 Jul; 54(7):2250-62. PubMed ID: 16802364
[TBL] [Abstract][Full Text] [Related]
9. Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis.
Erre GL; Passiu G
Reumatismo; 2009; 61(2):90-7. PubMed ID: 19633795
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway.
Sambo P; Baroni SS; Luchetti M; Paroncini P; Dusi S; Orlandini G; Gabrielli A
Arthritis Rheum; 2001 Nov; 44(11):2653-64. PubMed ID: 11710721
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion.
Tinazzi E; Dolcino M; Puccetti A; Rigo A; Beri R; Valenti MT; Corrocher R; Lunardi C
Arthritis Res Ther; 2010; 12(4):R131. PubMed ID: 20609215
[TBL] [Abstract][Full Text] [Related]
12. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis.
Servettaz A; Guilpain P; Goulvestre C; Chéreau C; Hercend C; Nicco C; Guillevin L; Weill B; Mouthon L; Batteux F
Ann Rheum Dis; 2007 Sep; 66(9):1202-9. PubMed ID: 17363403
[TBL] [Abstract][Full Text] [Related]
13. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy.
Filaci G; Cutolo M; Scudeletti M; Castagneto C; Derchi L; Gianrossi R; Ropolo F; Zentilin P; Sulli A; Murdaca G; Ghio M; Indiveri F; Puppo F
Rheumatology (Oxford); 1999 Oct; 38(10):992-6. PubMed ID: 10534551
[TBL] [Abstract][Full Text] [Related]
15. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
Rehberger P; Beckheinrich-Mrowka P; Haustein UF; Sticherling M
Acta Derm Venereol; 2009; 89(3):245-9. PubMed ID: 19479119
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
Mittag M; Beckheinrich P; Haustein UF
Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
[TBL] [Abstract][Full Text] [Related]
17. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.
Cutolo M; Zampogna G; Vremis L; Smith V; Pizzorni C; Sulli A
J Rheumatol; 2013 Jan; 40(1):40-5. PubMed ID: 23118114
[TBL] [Abstract][Full Text] [Related]
18. A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.
Taniguchi T; Miyagawa T; Tamaki Z; Nakamura K; Yamashita T; Saigusa R; Takahashi T; Toyama T; Ichimura Y; Yoshizaki A; Tada Y; Sugaya M; Kadono T; Sato S; Asano Y
Arch Dermatol Res; 2017 Dec; 309(10):833-842. PubMed ID: 29038846
[TBL] [Abstract][Full Text] [Related]
19. Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: in Vitro Evidence.
Manetti M; Romano E; Rosa I; Fioretto BS; Guiducci S; Bellando-Randone S; Pigatto E; Cozzi F; Ibba-Manneschi L; Matucci-Cerinic M
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817940
[TBL] [Abstract][Full Text] [Related]
20. Iloprost infusion does not reduce oxidative stress in systemic sclerosis.
Volpe A; Biasi D; Caramaschi P; Bambara LM; Carletto A; Degan M; Minuz P
Rheumatol Int; 2008 Feb; 28(4):335-7. PubMed ID: 17704920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
